Correction to “Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines”
نویسندگان
چکیده
منابع مشابه
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
Production of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic carrier protein such as Cross-Reactive-Material-197 (CRM197). Instead of using glycans from natural sources recent vaccine development has been focusing on the use of synthetically defined minimal epitopes. While the glycan is structurally defined, the attachment sites on the protein are not. Fu...
متن کاملTBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracti...
متن کاملNovel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
Although glycoconjugate vaccines are generally very efficacious, there is still a need to improve their efficacy, especially in eliciting a strong primary antibody response. We have recently described a new type of vaccine adjuvant based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highly efficacious at enhancing immunogenicity of protein based vaccines. Since no adjuvant has been s...
متن کاملNew approaches to glycoconjugate synthesis
Absnuct: Generally convergent strategies are employed in glyconjugate synthesis, hence the oligosaccharide moiety and the aglycon moiety are separately prepared and then linked to yield the target molecule; for glycopeptides linear synthesis strategies are more successful. The importance of p-glycosidic linkages of glucosamine and galactosamine in glycoconjugates was reason for the development ...
متن کاملHow Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?
There is a growing appreciation for the role of vaccines in confronting the problem of antimicrobial resistance (AMR). Vaccines can reduce the prevalence of resistance by reducing the need for antimicrobial use and can reduce its impact by reducing the total number of cases. By reducing the number of pathogens that may be responsible for a particular clinical syndrome, vaccines can permit the u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Accounts of Chemical Research
سال: 2017
ISSN: 0001-4842,1520-4898
DOI: 10.1021/acs.accounts.7b00256